Clinical & Experimental Allergy,
Год журнала:
2024,
Номер
unknown
Опубликована: Окт. 4, 2024
Allergic
asthma
is
the
predominant
phenotype
among
asthmatics.
Although
conventional
pharmacotherapy
a
central
component
in
management
of
asthma,
it
does
not
enable
control
symptoms
all
patients.
In
recent
decades,
some
uncontrolled
asthmatic
patients,
especially
those
with
allergic
have
benefited
from
biological
therapies.
However,
biologics
do
address
unmet
needs
left
by
pharmacotherapy.
Furthermore,
noteworthy
that
neither
nor
therapies
disease-modifying
properties.
this
context,
allergen
immunotherapy
(AIT)
represents
an
indispensable
therapeutic
arsenal
against
due
to
its
immunological
effects.
review
article,
funded
AIT
manufacturer,
we
find
clinical
trials
support
as
only
treatment
option
able
both
improve
and
prevent
onset
worsening
condition.
For
patients
severe
or
other
safety
concerns,
combination
offers
very
promising
new
modalities
for
asthma.
Trial
Registration:
clinicaltrials.gov
identifier:
NCT06027073.
Allergologie select,
Год журнала:
2021,
Номер
5(01), С. 349 - 360
Опубликована: Янв. 1, 2021
Allergic
rhinoconjunctivitis
(hay
fever)
is
the
most
common
chronic
disease
in
all
industrialized
nations.
Therapy
consists
essentially
use
of
anti-allergic
and
anti-inflammatory
drugs,
which
mostly
show
a
good
quick
effect.
With
allergen-specific
immunotherapy,
there
also
causal
possibility
tolerance
induction.
There
currently
considerable
undersupply,
as
those
affected
trivialize
symptoms
often
have
concerns
about
long-term
drug
therapy.
great
interest
using
non-medicinal
measures
to
prevent
and/or
relieve
allergic
on
assumption
that
these
are
free
from
side
effects.
In
this
publication,
we
present
non-drug
methods
for
clinical
studies
available
literature.
The
varying
degrees
effectiveness.
An
evidence-based
comparative
assessment
between
not
possible.
hardly
any
comparison
standard
A
large
number
interventions
consist
allergen
reduction,
e.g.,
with
air
filters,
or
cleaning
mucous
membranes
nasal
irrigation,
etc.,
none
should
be
seen
substitute
but
supplement
Allergologie select,
Год журнала:
2022,
Номер
6(01), С. 248 - 258
Опубликована: Янв. 1, 2022
The
great
milestones
in
medicine
almost
always
have
their
precursors,
which
help
the
event
to
break
through.
So
it
was
with
allergen-specific
immunotherapy
(AIT)
and
work
of
Noon
Freeman
world-renowned
publication
1911.
In
this
article,
we
want
outline
AIT's
long
journey,
from
early
attempts
achieve
tolerance
allergens
environment.
Many
very
different
methods
were
used;
homeopathy
use
recombinant
allergens.
Initially,
allergen
extracts
given
only
subcutaneously,
but
then
also
through
other
routes,
such
as
nasal,
rectal,
intradermal,
epicutaneous,
lymph
nodes,
or
oral.
It
merit
Bill
Franklin,
whom
many
us
still
experienced
active
participants
congresses,
point
out
that
effect
AIT
must
be
documented
not
by
clinical
observation
a
controlled
form
including
placebo
injections.
thus
transferred
evidence-based
medicine,
successfully
apply
today.
We
would
like
express
our
gratitude
Franklin
himself
all
others
involved
development
summary
111
years
immunotherapy.
Current Pharmaceutical Design,
Год журнала:
2024,
Номер
30(12), С. 887 - 901
Опубликована: Март 29, 2024
Abstract:
Allergic
rhinitis
(AR)
is
an
IgE-mediated
atopic
disease
that
occurs
due
to
inhaled
antigens
in
the
immediate
phase.
Misdiagnosis,
insufficient
treatment,
or
no
treatment
at
all
are
frequent
problems
associated
with
widespread
condition
known
as
chronic
allergic
rhinitis.
AR
symptoms
include
runny,
itchy,
stuffy,
and
sneezing
noses.
Asthma
nasal
polyps,
for
example,
sometimes
occur
simultaneously
patients.
In
order
people
living
be
comfortable
productive
possible,
should
center
on
reducing
their
symptoms.
The
online
sources
literature,
such
Pubmed,
ScienceDirect,
Medline,
were
reviewed
gather
information
regarding
therapeutic
modalities
of
evidence-based
treatments
objectives
present
study.
An
increasing
number
suffering
from
AR,
resulting
a
heavy
financial
medical
burden
healthcare
systems
around
world.
Undertreating
frequently
results
decline
quality
life.
Treatment
compliance
critical
challenge
administration
AR.
Innovative
therapies
needed
RA
provide
patients
symptom
alleviation
less
expensive,
more
effective,
longer
duration
action.
Evidence-based
guidelines
helpful
managing
illness.
Treating
according
standards
can
help
management.
includes
allergen
avoidance,
drug
therapy,
immunotherapy,
patient
education,
follow-up.
However,
intranasal
corticosteroids
popular.
Hence,
this
review
article,
options
discussed
depth.
We
also
incidence,
causes,
new
clinical
condition.
Clinical & Experimental Allergy,
Год журнала:
2024,
Номер
unknown
Опубликована: Окт. 4, 2024
Allergic
asthma
is
the
predominant
phenotype
among
asthmatics.
Although
conventional
pharmacotherapy
a
central
component
in
management
of
asthma,
it
does
not
enable
control
symptoms
all
patients.
In
recent
decades,
some
uncontrolled
asthmatic
patients,
especially
those
with
allergic
have
benefited
from
biological
therapies.
However,
biologics
do
address
unmet
needs
left
by
pharmacotherapy.
Furthermore,
noteworthy
that
neither
nor
therapies
disease-modifying
properties.
this
context,
allergen
immunotherapy
(AIT)
represents
an
indispensable
therapeutic
arsenal
against
due
to
its
immunological
effects.
review
article,
funded
AIT
manufacturer,
we
find
clinical
trials
support
as
only
treatment
option
able
both
improve
and
prevent
onset
worsening
condition.
For
patients
severe
or
other
safety
concerns,
combination
offers
very
promising
new
modalities
for
asthma.
Trial
Registration:
clinicaltrials.gov
identifier:
NCT06027073.
